Researchers in the past have identified Bcl-2 as a predictive marker of patient response to immunotherapy in clinical samples of metastatic renal cell carcinoma[65], raising the possibility of targeting Bcl-2 to enhance the vulnerability of cancer cells to immunotherapies[66]. This evidence concerns the gene BCL2 and cancer.